2.2. Pediatrics

Although treatment durations have not been solidified, experts recommend that dalteparin therapy should be continued for less than or equal to 3 months in pediatric patients with provoked DVT or PE and up to 12 months (range, 6 to 12 months) in pediatric patients with unprovoked DVT or PE¹⁴. Dalteparin treatment recommendations for pediatric patients are summarized in Table 4.

Table 4. LMWH Recommended Treatment Duration (Pediatric Patients) ^1,2,4,15

Treatment Indication	Drug Name	Treatment Duration Range	Maximum Treatment Duration
Venous thromboembolism treatment	Dalteparin	3 to 12 months	12 months